World Boxing Champion Mairis Briedis Joins Cancer Fighting Team

Riga, Latvia, July 14, 2016 (Newswire.com) - World boxing champion Mairis Briedis has become the Head of Security of the Rigvir holding, manufacturer of unique cancer medicine, at the same time continuing his professional boxing career.

Mairis Briedis, the Head of Security of Rigvir holding: "I have always find it important to make my social life and career also outside sports and I have successfully managed to balance both of them. I am truly honoured to be a part of Rigvir team accomplishing the work of saving people's lives, which is so important and highly regarded among our people and around the world! I hope this unique scientific achievement will help as many as possible in their fight against cancer."

I am truly honoured to be a part of Rigvir team accomplishing the work of saving people's lives, which is so important and highly regarded among our people and around the world! I hope this unique scientific achievement will help as many as possible in their fight against cancer.

Mairis Briedis, Head of Security of Rigvir Holding

Mairis Briedis is the current International Boxing Federation (IBF) Inter-Continental Cruiserweight title holder since February 2016. He is also the current International Boxing Association (IBA) Cruiserweight Champion since 2013. After successful fight in May 2016 Mairis Briedis became current mandatory challenger for WBC Cruiserweight title. Mairis Briedis has won 20 out of 20 fights in his boxing career. Mairis Briedis was named the European Person of the Year 2014 in Latvia.

Rigvir holding is the manufacturer of unique cancer medicine, which is able to find and destroy malignant tumour cells in the human body. This kind of cancer treatment, called oncolytic virotherapy, is evidence based and recognised as safe and effective therapy. Study published by Melanoma research suggests that a significant number of melanoma patients would benefit from prolonging the survival with oncolytic virotherapy treatment, moreover this can be achieved without serious side effects.

Rigvir is approved for melanoma treatment in 2004 by State Agency of Medicines of Latvia, EU member state, however in clinical practice it has been also used for treatment of several other malignant tumours. Cancer patients from over 50 countries have already received oncolytic virotherapy.

Source: Rigvir